EGFR and non-small cell lung carcinoma: - Phase I trial in EGFR TKI-naïve and –treated NSCLC patients- Combination of atezolizumab and erlotinib was well tolerated and it exhibited favorable efficacy compared with prior reports of erlotinib monotherapy. ORR = 75% and median PFS = 15.4 months